import { ToolReview } from "@/lib/types";

export const gptRosalind: ToolReview = {
  slug: "gpt-rosalind",
  name: "GPT-Rosalind (OpenAI)",
  tagline: "OpenAI's first domain-specific model -- life sciences, drug discovery, translational medicine. Launched 2026-04-16 as a Trusted Access research preview. Launch partners: Amgen, Moderna, Allen Institute, Thermo Fisher. Paired with a Life Sciences Codex plugin (50+ scientific tool integrations)",
  category: "ai-llms",
  url: "https://openai.com/index/introducing-gpt-rosalind/",

  scores: {
    easeOfUse: 3,
    outputQuality: 9,
    value: 7,
    features: 8,
    overall: 6.8,
  },

  hasFreeTier: false,
  pricing: [
    {
      plan: "Trusted Access (gated)",
      price: "Invite only",
      features: [
        "Research preview limited to partner organizations",
        "Launch partners: Amgen, Moderna, Allen Institute for Cell Science, Thermo Fisher",
        "Application required via OpenAI enterprise sales",
        "Not available to consumer ChatGPT users",
      ],
    },
    {
      plan: "Life Sciences Codex Plugin",
      price: "Included with ChatGPT Pro / Business",
      features: [
        "50+ scientific tool integrations (PubMed, BioRxiv, UniProt, etc.)",
        "Works with Codex cloud agent for multi-step research workflows",
        "Available in ChatGPT Pro ($100/mo) and Business tiers",
      ],
    },
    {
      plan: "Public access",
      price: "Not available",
      features: [
        "Not being released publicly as a standalone product",
        "Consumer use case unclear -- this is an enterprise / research tool",
      ],
    },
  ],

  pros: [
    "OpenAI's first named vertical/domain-specific model -- signals a new strategy beyond general-purpose GPT-5.x. The pattern (vertical + gated rollout + blue-chip launch partners) echoes the 2026-04-07 Anthropic Mythos Preview / Project Glasswing model and suggests how frontier-lab productization will work in 2026 and beyond",
    "Launch partners Amgen, Moderna, Allen Institute, Thermo Fisher are credible biotech and research institutions -- not just splashy logos. Suggests the model has been meaningfully trained/tuned on real biology data with real domain expertise in the loop",
    "Life Sciences Codex plugin is the practical hook -- 50+ scientific tool integrations (PubMed, BioRxiv, UniProt, scientific Python libraries) mean Codex can now run multi-step research workflows: literature search, protein lookup, reagent ordering scripts, experimental design in one chain",
    "OpenAI is now playing in the space Anthropic's Mythos targets (gated domain models) with Nvidia's vertical strategy (BioNeMo, Evo) and Google's Med-PaLM lineage. Competition drives rapid improvement",
  ],
  cons: [
    "Not available to anyone reading this unless your org is already a Trusted Access partner. If you are at Amgen or Moderna, ask internally. Everyone else: wait and see",
    "Domain-specific model, so for general-purpose work Opus 4.7, GPT-5.4, or Gemini 3.1 Pro remain the right answer -- GPT-Rosalind will be narrower in scope even once broadly available",
    "Trusted Access means OpenAI controls who uses it. Unlike consumer ChatGPT, there is no path from 'I am curious' to 'I am using it' without an enterprise sales conversation",
    "Claims need third-party verification. At launch, OpenAI has not published open benchmarks. Expect published drug-discovery / biology evals from neutral sources over next 3-6 months",
  ],
  knownIssues: [
    {
      description: "Trusted Access rollout -- not open for self-serve signup. Launched 2026-04-16 with fewer than 10 named partners. Broader access timeline not announced",
      source: "OpenAI launch post",
      date: "2026-04",
    },
    {
      description: "No independently-published benchmark results yet. OpenAI's claims (life-science reasoning superiority over general-purpose GPT-5.x) rely on internal evaluations. Wait for neutral published comparisons over Q2/Q3 2026",
      source: "VentureBeat, OpenAI launch coverage",
      date: "2026-04",
    },
  ],
  bestFor: "Researchers and enterprises in biology, drug discovery, protein science, translational medicine, or adjacent life-sciences domains who can get Trusted Access. Also relevant to anyone building life-sciences AI products who needs to understand where OpenAI's vertical strategy is heading.",
  notFor: "General-purpose use (use GPT-5.4, Opus 4.7, or Gemini 3.1 Pro). Consumer users who are not in a partner org (no access available). Anyone expecting standalone consumer pricing -- this is an enterprise / research play only.",
  verdict: "GPT-Rosalind is OpenAI's first named vertical model, launched 2026-04-16 as a Trusted Access preview with Amgen, Moderna, Allen Institute, and Thermo Fisher as launch partners. The parallel to Anthropic's Mythos Preview (2026-04-07) is clear: frontier labs are shipping gated domain-specific models while keeping their general-purpose models (GPT-5.x, Opus 4.x) publicly accessible. For life-sciences researchers in those partner orgs, this is a real capability upgrade worth exploring. For everyone else, it is a strategic signal: expect GPT-[domain] models in law, finance, defense, and other verticals through 2026, and expect broad availability never to materialize for the most capable tiers. The bundled Life Sciences Codex plugin (50+ scientific tool integrations) is the more immediately actionable item -- ChatGPT Pro and Business users can run multi-step life-sciences research workflows with it starting today.",

  lastReviewedDate: "2026-04-17",
  dataSources: [
    { name: "OpenAI: Introducing GPT-Rosalind", url: "https://openai.com/index/introducing-gpt-rosalind/", dateAccessed: "2026-04-17" },
    { name: "VentureBeat: OpenAI debuts GPT-Rosalind + Codex plugin", url: "https://venturebeat.com/technology/openai-debuts-gpt-rosalind-a-new-limited-access-model-for-life-sciences-and-broader-codex-plugin-on-github", dateAccessed: "2026-04-17" },
    { name: "Industry analysis of vertical AI strategy", dateAccessed: "2026-04-17" },
  ],
  affiliateUrl: "https://openai.com/index/introducing-gpt-rosalind/",
  status: "active",
  metaTitle: "GPT-Rosalind Review (April 16 2026): OpenAI's First Vertical Model -- Life Sciences",
  metaDescription: "GPT-Rosalind review. OpenAI's first domain-specific model -- life sciences, drug discovery, translational medicine. Trusted Access launch with Amgen, Moderna, Allen Institute.",
};
